What a Coronary Calcium Score Really Tells You

What does a coronary calcium score actually measure?

A coronary artery calcium (CAC) scan is a fast CT of the heart that counts calcified plaque already sitting in your coronary arteries and converts it into a single number, the Agatston score. That number is not a prediction of the future so much as a record of the past: it measures atherosclerosis that has already formed and hardened. A score of zero means no detectable calcified plaque, which usually places you in a very low risk band, while a score above 100 signals a meaningful plaque burden and higher risk. The strongest, most defensible use of the test is narrow. It works best as a tiebreaker when a standard risk estimate leaves a statin decision genuinely uncertain, not as a routine screen for everyone. This article is general education, not medical advice.

How the score is built, and what it does not see

The scanner assigns points based on how much calcium is present and how dense it is, then sums those points across the coronary arteries. Because calcium is easy to spot on CT and hard to confuse with anything else, the measurement is reproducible and does not require contrast dye or a treadmill.

The blind spot matters. CAC counts only plaque that has calcified. Soft, non-calcified plaque, the kind that can be more prone to rupture, does not register. This is why a young person with early, still-soft disease can have a score of zero, and why the test is far more informative in middle age and beyond, when calcification has had time to appear. A zero is reassuring, but it is a statement about calcified disease, not a guarantee that arteries are pristine.

Why zero and why over 100 change the picture

The reason a calcium score earns its place is that it reclassifies people whom a standard calculator gets wrong. Traditional tools, such as the pooled cohort equations, estimate risk from age, blood pressure, cholesterol, smoking, and diabetes. They are decent at the population level and clumsy for the individual, especially in the wide middle band where the recommendation could reasonably go either way.

A zero score pulls many of those middle-band people down. A 2025 review in Cureus by Chaparala and colleagues describes the pattern clearly: people with a zero score have very low event rates over the following decade, with what the authors call a long warranty period, and in the absence of red flags they may reasonably defer statin therapy. This is the evidence behind what clinicians call the de-risking effect.

A high score pushes in the other direction. The same review notes that once calcium climbs above 100, the projected ten-year risk of a major cardiovascular event generally clears the 7.5 percent threshold at which statin therapy is recommended. A 2024 paper in JACC: Advances by Maron and colleagues goes further, proposing a staging scheme in which a score of 300 or more carries risk the authors describe as similar to someone who has already had a heart attack, and a score of 1,000 or more marks extreme risk. That paper is explicitly a proposal and call to action, not an adopted guideline, and its authors are careful to note that the benefit of preventive therapy based on calcium severity is not yet fully established.

Why it is a tiebreaker, not a routine screen

Two facts keep the calcium score in a supporting role. First, guidelines already reserve it for uncertainty. The 2018 ACC/AHA cholesterol guideline positions CAC as reasonable for adults roughly 40 to 75 with borderline or intermediate risk when the decision to start a statin remains unclear after the usual assessment. It is a way to break a tie, and a tie is the precondition for ordering it.

Second, the body that judges population screening has not endorsed CAC as a routine test. The U.S. Preventive Services Task Force, in its 2022 statement on statins for primary prevention, did not fold calcium scoring into its statin criteria and instead pointed to a separate assessment. That reticence is not a dismissal of the science; it reflects the difference between a test that helps a specific undecided patient and a test that should be run on the general public. Screening everyone would expose many people to scans, radiation, incidental findings, and downstream testing in order to reclassify a few, which is a poor trade when a standard calculator already gives a confident answer.

The practical logic follows from this. If your estimated risk is clearly low, a scan rarely changes anything. If it is clearly high, treatment is already indicated and the scan is redundant. The value concentrates in the uncertain middle, where a zero can spare someone years of unnecessary medication and a high score can convert an abstract percentage into a reason to act.

What the number cannot do for you

A calcium score is a snapshot of accumulated disease, and it is quiet on several things people wish it would answer. It does not tell you whether a specific plaque will rupture next year. It does not track soft plaque. It does not, on its own, set a treatment; it feeds a conversation that also weighs your other risk factors, your preferences, and the strength of the evidence behind any medication. And a zero today does not license ignoring blood pressure, smoking, or cholesterol, because the underlying biology keeps moving even when the calcium number is flattering.

Used within those limits, the test is genuinely useful. It turns a debatable risk estimate into a more grounded one and helps two people with the same calculator output make different, better-fitted decisions. The evidence supports exactly that role and no more.